H.C. Wainwright Believes Strata Skin Sciences Inc (SSKN) Still Has Room to Grow


H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Strata Skin Sciences Inc (NASDAQ: SSKN) today and set a price target of $5. The company’s shares closed yesterday at $3.49, close to its 52-week high of $3.88.

Pantginis commented:

“Valuation and risks to price target achievement. We maintain our Buy rating and are increasing our price target to $5 from $3. The primary drivers to our valuation change include: (1) adjustment to base year; (2) increasing our XTRAC peak sales estimate for psoriasis from $55 million to $65 million; and (3) increasing our XTRAC peak sales estimate for vitiligo from $25 million to $35 million.”

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.0% and a 37.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Strata Skin Sciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.

See today’s analyst top recommended stocks >>

Based on Strata Skin Sciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.36 million. In comparison, last year the company had a GAAP net loss of $13.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts